|
Report No. : |
345974 |
|
Report Date : |
24.10.2015 |
IDENTIFICATION DETAILS
|
Name : |
MARPEL PHARMA GUATEMALA SA |
|
|
|
|
Registered Office : |
3 Calle A 4-24 Z.10 Interior, Guatemala City |
|
|
|
|
Country : |
Guatemala |
|
|
|
|
Date of Incorporation : |
10.11.2009 |
|
|
|
|
Legal Form : |
Sociedad Anonima |
|
|
|
|
Line of Business : |
Supplier of Pharmaceutical Products. |
|
|
|
|
No. of Employees : |
16 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
Guatemala |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
GUATEMALA - ECONOMIC
OVERVIEW
Guatemala is the most populous country in Central America
with a GDP per capita roughly one-half that of the average for Latin America
and the Caribbean. The agricultural sector accounts for 13.7% of GDP and 32% of
the labor force; key agricultural exports include sugar, coffee, bananas, and
vegetables. The 1996 peace accords, which ended 36 years of civil war, removed
a major obstacle to foreign investment, and since then Guatemala has pursued
important reforms and macroeconomic stabilization. The Dominican
Republic-Central America Free Trade Agreement (CAFTA-DR) entered into force in
July 2006, spurring increased investment and diversification of exports, with
the largest increases in ethanol and non-traditional agricultural exports.
While CAFTA-DR has helped improve the investment climate, concerns over
security, the lack of skilled workers, and poor infrastructure continue to
hamper foreign direct investment. The distribution of income remains highly
unequal with the richest 20% of the population accounting for more than 51% of
Guatemala's overall consumption. More than half of the population is below the
national poverty line, and 13% of the population lives in extreme poverty.
Poverty among indigenous groups, which make up more than 40% of the population,
averages 73%, with 22% of the indigenous population living in extreme poverty.
Nearly one-half of Guatemala's children under age five are chronically
malnourished, one of the highest malnutrition rates in the world. Guatemala is
the top remittance recipient in Central America as a result of Guatemala's
large expatriate community in the United States. These inflows are a primary
source of foreign income, equivalent to one-half of the country's exports or
one-tenth of its GDP. In November 2014 along with his counterparts from El
Salvador and Honduras, President PEREZ MOLINA announced the “Plan of the
Alliance for Prosperity in the Northern Triangle.” This plan seeks to address
the challenges facing the three Northern Triangle countries, including steps
the governments will take to stimulate economic growth, increase transparency
and fiscal responsibility, reduce violence, modernize the justice system,
improve infrastructure, and promote educational opportunities over the next several
years.
|
Source
: CIA |
|
IDENTIFICATION |
|||
|
Ordered as: |
MARPEL PHARMA GUATEMALA SA |
||
|
Address in the order: |
3A CALLE A4-24 ZONE 10 INTERIOR A 01010, |
||
|
Legal Name: |
MARPELPHARMA GUATEMALA SA |
||
|
Trade Name: |
MARPEL PHARMA GUATEMALA |
||
|
Legal Address |
3 Calle A 4-24 Z.10 Interior |
||
|
Postal Town |
Guatemala City |
||
|
Post Code |
N.A. |
||
|
Primary Geographic Area |
Guatemala |
||
|
Country |
GT |
||
|
Operative Address |
3 Calle A 4-24 Z.10 Interior Guatemala City, Guatemala |
||
|
Telephone: |
+502 2360 8484 / +502 2360 8483 |
NIT : |
67680895 |
|
Fax: |
+502 2360 8466 |
Legal Form: |
Sociedad Anonima |
|
Email: |
m.ramazzini@marpelpharma.com /
m.ramirez@marpelpharma.com |
Registered in: |
GT |
|
Website: |
http://marpelpharma.com/ |
Date Created: |
2009 |
|
Manager: |
Mateo Estuardo Menendez Ramazzini, General
Manager |
Date Incorporated: |
November 10th, 2009 |
|
Staff: |
16 |
Stock: |
N.A. |
|
|
|
Value: |
N.A |
|
Activity: |
Pharmaceutical products supplier |
||
|
Management: |
|
|
|
Mateo Estuardo Menendez Ramazzini, General
Manager Samuel Sosa, Sales Manager Mario Ramirez, Finacial Manager |
|
Legal Filings |
|
The sources consulted record no detrimental
legal or labor court information. |
|
Public |
NO |
|
Shareholders |
|
|
Listed at the stock exchange: |
|
|
|
NO |
|
Shareholders Parent Company(ies): |
|
This is a private company. The company is a
subsidiary of Marpel Pharma SA of Costa Rica.
Edificio Multibodegas Bodega # 7 Del Cruce de
Multiplaza Escazu
800 metros Noroeste
San Jose
Costa Rica
Tel.: (506) 2215-4215
Fax: (506) 2215-4214
|
Payments |
REGULAR |
|
RELATED
COMPANIES: |
|
|
|
Marpel Pharma SA has other subsidiaries in
Honduras, Mexico, El Salvador and Argentina. |
|
FINANCIALS
- COMMERCIAL TRENDS AND FORECAST |
|
As a private company the subject does not
publish any financial statements. |
|
We have contacted the company but could not
reach anyone who could provide us any financial data. |
|
However our financial sources could provide
us with the following data. Those figures are estimates provided by
confidential banking and financial institutions working with the company. |
|
Currency |
DATE |
|
USD |
2011 |
|
Turnover |
2 400 000 |
|
The cash flow is |
Normal |
Comments on the financial data: This
information was not verified by the company.
It was not possible to obtain more recent financial data for this subject.
|
FINANCIAL
SUMMARY |
|
|
Profitability |
N.A. |
|
Indebtedness |
CONTROLLED |
|
Cash |
NORMAL |
N/A
|
GEOPOLITICS - GUATEMALA |
|
|
POLITICAL DATA |
ECONOMIC DATA |
|
Form of Government: Republic Economic Risk: Low |
Currency: 1,00 USD = 7,66950 GTQ |
|
BANKS |
|
|
Name of the Bank |
Banco Promerica Guatemala |
|
Location |
v. Reforma 9-55 Z. 10 Edificio Reforma 10
2do nivel, Guatemala, CA 01010 |
|
Comments |
This information was not verified by the
company. |
|
BUSINESS HISTORY |
|
|
|
The company was created and incorporated in
Guatemala in 2009. |
|
PRINCIPAL ACTIVITY |
|
|
|
Distribution of pharmaceutical products |
|
Products/Services description: |
|
|
|
The company distributes three product
lines: Pharmaceuticals Biomedical equipment Veterinary products |
|
Sales are: |
|
|
|
Wholesale |
|
Brands: |
|
|
|
Sages products, Medicall Actions, Histo |
|
Clients: |
|
|
|
Professionals of industry such as: Farmedical SRL (Mexico) The company has experience working as a government
supplier, having been awarded 624 contracts between 2010 and 2015 for a total
of GTQ 13 944 792.64. |
|
Suppliers: |
|
|
|
It was not possible to obtain the name of
any suppliers for this subject. |
|
Operations area: |
|
|
|
National, International |
|
The company imports from Worldwide,
depending on the need |
|
|
The company exports to Mexico |
|
|
Trade References: |
|
|
|
It was not possible to obtain trade
references for this subject. |
|
The subject employs 16 employee(s) |
|
|
Comments on staff: |
|
|
|
This information was not verified by the
company. |
|
PAYMENTS |
|
|
|
regular |
|
LOCATION |
|
|
Headquarters |
|
|
|
3 Calle A 4-24 Z.10 Interior Guatemala City, Guatemala |
|
Comments on location: |
|
|
|
This information was not verified by the
company. |
|
Branches: |
|
|
|
We could not locate any company branches. |
Final
Opinion
This is a small Guatemalan company that has
been in operations in the country since 2009.
The company distributes all kinds of pharmaceutical
products.
The company imports from abroad, so its
future prospects will be tied to the ease of bringing those products into the
country.
The company also exports abroad, so it can
have a much larger market reach than its size would imply.
The company has experience working as a
government supplier, having been awarded several contracts in the last 5 years.
The company works with a well-known bank in
the country.
There were no legal filings found against the
company.
|
APPENDIX |
|
|
Person Interviewed |
|
|
|
Mario Ramirez |
|
Position |
|
|
|
Financial Manager |
|
Comments |
|
|
|
We contacted the company and the operator
told us Mr. Ramirez was not available to take our call, and asked us to email
him to verify the necessary information. We did so and are awaiting a reply. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.64.88 |
|
|
1 |
Rs.99.89 |
|
Euro |
1 |
Rs.72.06 |
INFORMATION DETAILS
|
Analysis Done by
: |
KIN |
|
|
|
|
Report Prepared
by : |
NIT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.